|
CANCER PROGRESSION AND TUMOR CELL MOTILITY
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
G388R mutation of the FGFR4 gene is not relevant for breast cancer prognosis.
|
14710228 |
2004 |
|
Malignant neoplasm of breast
|
|
0.050 |
GeneticVariation
|
BEFREE |
G388R mutation of the FGFR4 gene is not relevant for breast cancer prognosis.
|
14710228 |
2004 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
BEFREE |
Gly-388Arg polymorphism of FGFR-4 most likely contributes to susceptibility to prostate cancer, especially in men of European descent.
|
21625079 |
2011 |
|
Prostate carcinoma
|
|
0.080 |
GeneticVariation
|
BEFREE |
Gly-388Arg polymorphism of FGFR-4 most likely contributes to susceptibility to prostate cancer, especially in men of European descent.
|
21625079 |
2011 |
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
A gly(388)arg polymorphism (rs351855) in the transmembrane domain of the fibroblast growth factor receptor (FGFR4) is associated with increased risk, staging, and metastasis in several different types of cancer.
|
22971346 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A gly(388)arg polymorphism (rs351855) in the transmembrane domain of the fibroblast growth factor receptor (FGFR4) is associated with increased risk, staging, and metastasis in several different types of cancer.
|
22971346 |
2012 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
A gly(388)arg polymorphism (rs351855) in the transmembrane domain of the fibroblast growth factor receptor (FGFR4) is associated with increased risk, staging, and metastasis in several different types of cancer.
|
22971346 |
2012 |
|
Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Malignant neoplasm of breast
|
|
0.050 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Malignant Head and Neck Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Head and Neck Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Sarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Sarcoma of soft tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
A common single nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas.
|
23226373 |
2012 |
|
Node-positive breast cancer
|
|
0.020 |
GeneticVariation
|
BEFREE |
A recent study presented first evidence that a single nucleotide polymorphism (SNP) at codon 388 of fibroblast growth factor receptor 4 (FGFR4) gene, causing a transmembrane domain missense mutation (Gly388Arg), is associated with disease outcome in node-positive breast cancer.
|
16822847 |
2006 |
|
Malignant neoplasm of prostate
|
|
0.780 |
GeneticVariation
|
UNIPROT |
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.
|
18670643 |
2008 |
|
Malignant neoplasm of stomach
|
|
0.020 |
GeneticVariation
|
BEFREE |
Although we observed no correlation between the FGFR4 Gly388Arg polymorphism and clinicopathological parameters or survival in the total cohort of GC patients, the presence of the Arg388 allele was associated with shorter survival time in patients with GC if the tumor was small (log rank χ(2) = 5.449, P = 0.020), well differentiated (log rank χ(2) = 12.798, P = 0.000), T1 or T2 stage (log rank χ(2) = 4.745, P = 0.029), without lymph node involvement (log rank χ(2) = 6.647, P= 0.010), and at an early clinical stage (log rank χ(2) = 4.615, P = 0.032).
|
23901234 |
2013 |
|
Stomach Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Although we observed no correlation between the FGFR4 Gly388Arg polymorphism and clinicopathological parameters or survival in the total cohort of GC patients, the presence of the Arg388 allele was associated with shorter survival time in patients with GC if the tumor was small (log rank χ(2) = 5.449, P = 0.020), well differentiated (log rank χ(2) = 12.798, P = 0.000), T1 or T2 stage (log rank χ(2) = 4.745, P = 0.029), without lymph node involvement (log rank χ(2) = 6.647, P= 0.010), and at an early clinical stage (log rank χ(2) = 4.615, P = 0.032).
|
23901234 |
2013 |
|
Node-positive breast cancer
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analyses of the disease characteristics showed that SNP rs351855 was associated with lymph-node-positive breast cancer with a dose-dependent effect of the minor allele (P = 0.008).
|
26431494 |
2015 |
|
Stomach Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Associations between FGFR4 Gly388Arg polymorphism and overall survival exist in patients with gastric cancer (P = 0.046).The FGFR4 Arg allele (hazard risk (HR), 2.324; 95% confidence interval (CI), 1.054-4.125; P = 0.037) and TNM stage (HR, 5.516; 95% CI 3.658-7.409; P = 0.005) were independent prognostic factors in patients with gastric cancer.
|
20844967 |
2010 |
|
Malignant neoplasm of stomach
|
|
0.020 |
GeneticVariation
|
BEFREE |
Associations between FGFR4 Gly388Arg polymorphism and overall survival exist in patients with gastric cancer (P = 0.046).The FGFR4 Arg allele (hazard risk (HR), 2.324; 95% confidence interval (CI), 1.054-4.125; P = 0.037) and TNM stage (HR, 5.516; 95% CI 3.658-7.409; P = 0.005) were independent prognostic factors in patients with gastric cancer.
|
20844967 |
2010 |
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical investigations of an FGFR4 germline polymorphism, resulting in substitution of glycine by arginine at codon 388 (G388 to R388), have shown a correlation between FGFR4 R388 and aggressive disease progression in cancer patients.
|
16109476 |
2006 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical investigations of an FGFR4 germline polymorphism, resulting in substitution of glycine by arginine at codon 388 (G388 to R388), have shown a correlation between FGFR4 R388 and aggressive disease progression in cancer patients.
|
16109476 |
2006 |
|
Low density lipoprotein cholesterol measurement
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Exome-wide association study of plasma lipids in >300,000 individuals.
|
29083408 |
2017 |